Journal Scans
Reduction of Elevated Plasma Osteopontin Levels With Resection of Non-Small-Cell Lung Cancer
Osteopontin Is a Potential Biomarker in Early-Stage NSCLC
JD Blasberg, HI Pass, CM Goparaju, RM Flores, S Lee, JS Donington
20100019
2010 Jan 19
J Clin Oncol
Reduction of Elevated Plasma Osteopontin Levels With Resection of Non-Small-Cell Lung Cancer
J Clin Oncol. 2010 Jan 19; Epub ahead of print, JD Blasberg, HI Pass, CM Goparaju, RM Flores, S Lee, JS Donington
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
As yet there is no biomarker for non–small cell lung cancer (NSCLC). A reliable biomarker would aid in screening high-risk populations, as well as in determining treatment for stage I patients, defining response to therapy, and monitoring for recurrence. Previous research suggests that osteopontin (OPN), a multifunctional glycophosphoprotein, plays a role in NSCLC pathogenesis. It is strongly overexpressed in NSCLC as compared with the normal lung. In early-stage disease, elevated OPN levels are...
